XML 29 R17.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
We operate as one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases. Segment profit or loss is measured as the net income (loss) reported on our Consolidated Statements of Operations and Comprehensive Income (Loss) and net income (loss) is used to monitor results. Our segment revenue consists of milestone payments, royalty payments, upfront license fees and transition services provided under our collaboration agreements, see Note 4. The measure of segment assets is reported on our Consolidated Balance Sheets as total assets.
The CODM is our Chief Executive Officer. The CODM manages the business activities on a consolidated basis in making decisions regarding resource allocation and performance assessment.
The following table is a summary of segment revenue, income (loss) and our significant expenses (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
Collaboration revenue$76,320 $30,017 $126,354 $48,167 
Operating expenses:
External R&D
Rosnilimab7,070 14,188 37,709 37,161 
ANB0337,519 1,631 15,248 7,276 
ANB1011,784 687 5,305 1,631 
ANB032(362)7,239 3,282 20,381 
Imsidolimab(1,204)2,389 (2,360)8,752 
Preclinical and other unallocated costs3,813 3,917 12,201 11,254 
Total External R&D(1)
18,620 30,051 71,385 86,455 
Total Internal R&D(2)
12,787 12,161 39,026 34,796 
Total R&D31,407 42,212 110,411 121,251 
External G&A(3)
2,247 2,529 10,223 6,980 
Internal G&A(2)
7,962 8,033 24,725 25,215 
Total G&A10,209 10,562 34,948 32,195 
Total operating expenses41,616 52,774 145,359 153,446 
Net income (loss) from operations
34,704 (22,757)(19,005)(105,279)
Interest income2,924 5,324 10,991 14,531 
Non-cash interest expense(22,515)(15,413)(60,182)(32,683)
Other income (expense), net— (5)5,433 (7)
Total other expense, net
(19,591)(10,094)(43,758)(18,159)
Income (loss) before income taxes
15,113 (32,851)(62,763)(123,438)
Provision for income taxes
— — (83)(9)
Segment net income (loss)
$15,113 $(32,851)$(62,846)$(123,447)
(1)     External R&D consists of costs associated with our research and development activities, including drug discovery efforts, preclinical and clinical development of our programs, manufacturing, and allocated facility-related costs.
(2)     Internal R&D and G&A consist of salaries and wages, stock-based compensation, recruiting and other employee benefits.
(3)     External G&A consists of general and administrative expenses including transaction costs, legal services, insurance, professional fees for auditing, tax, and market research, and allocated facility-related costs not otherwise included in research and development expenses.